A last comment on LAG3 inhibition and cancer. It
Post# of 148234
(Total Views: 503)
Posted On: 08/28/2024 4:58:36 AM
Re: Buddyboy20 #146024
A last comment on LAG3 inhibition and cancer.
It looks like Immutep is doing a study in soft-tissue sarcoma where they use the drug, along with radiation, before surgery. I hadn't heard that kind of approach before.The idea is it will affect the tumor microenvironment, shrink and/or compromise the tumor, and make the surgery easier/more effective.
Perhaps this is another use for leronlimab? I know it's not a priority, but the possibilities and potential are really monumental! And will manifest as more research gets done.
* * * *
One other thing I've been pondering... LL has utility in both acute indications (viral diseases, cancer, stroke/TBI) as well as chronic conditions (atherosclerosis, MASH/NASH, auto-immune diseases, HIV). So--how do you price a drug that saves lives in life-threatening indications, as well as saves lives by addressing chronic conditions?
I am assuming that for acute indications you take the drug until you recover, but for chronic illnesses you would take them forever, right? (Unless of course LL cures some of these chronic conditions...) Anyway, are there any drugs out there that are priced in a two-tiered system? In other words, one price for saving a life, a lower price for managing a condition for the rest of your life?
I would think the total addressable market for LL is going to be huge. And if you have a couple hundred million patients that would benefit, why not make it affordable? You wouldn't need a high price to make a boatload of money, for us as well as Cytodyn...
* * * *
Gotta bring the NP2 connection here. Most of you know Dr. Lalezari is a founding member and Vice Chairman of the Board of the non-profit pharmaceutical corporation NP2, right? From the website, their mission is to "disrupt the current for-profit model which doesn’t work for most Americans. Incorporating as a nonprofit means that the revenues generated from our drug sales will be re-invested into furthering our mission." Now all you hardcore capitalists out there, don't get your panties/boxers in a bunch! The idea is to manufacture and distribute oncology drugs when they go generic. With no marketing expenses and minimal R&D, they think they can really lower the cost of life-saving cancer drugs, which is their initial focus.
Just connecting the dots here, and answering the pricing question I posed earlier, but when leronlimab loses patent protection, I can see NP2 contracting the rights to it, producing it and selling at an affordable price. I know its difficult to manufacture and all that, but who better to work that out than Jacob Lalezari? And with 200 to 500 million people in the world who could use it, making it affordable is actually going to be necessary... Unless you want Cytodyn to bankrupt Medicare and every other country's health insurance systems!
Lots of talk recently about extending patent protection for as long as possible... Really? I'm here to make money, but as importantly, have an up-close view of the development of a life-saving and pharma-disruptive, history-making mab! Fer Christ sakes--as my Daddy used to say--I'm sure many of us here won't even live long enough to see our mab lose patent protection! So please, take off your greedypants, count your blessings before your bank account, and think about the planet and the big picture!
(And should we live long enough to see LL go off patent, there's a decent chance it'll be because of leronlimab! That right there is all the perspective anyone needs...).
And in the meantime, as we wait on the science and the publications and the clinical trials and the partnerships with for-profit pharma, we can sleep at night in good conscience. That, my friend, is priceless!
Well, didn't start this post intending to cover all this ground, or go on this length. I'll end with a big shout out to the board. Even the greedypants! Having a place like this to learn about all things CYDY and LL--with all the distinctive personalities and unique voices--is truly priceless! (I had no clue about NP2 and the Lalezari connection until one of you posted here with the link--thanks!).
Well, check out the NP2 website at np2.org
And here's a link, if I get it to work...
[https://np2.org/what-makes-us-unique/]
It looks like Immutep is doing a study in soft-tissue sarcoma where they use the drug, along with radiation, before surgery. I hadn't heard that kind of approach before.The idea is it will affect the tumor microenvironment, shrink and/or compromise the tumor, and make the surgery easier/more effective.
Perhaps this is another use for leronlimab? I know it's not a priority, but the possibilities and potential are really monumental! And will manifest as more research gets done.
* * * *
One other thing I've been pondering... LL has utility in both acute indications (viral diseases, cancer, stroke/TBI) as well as chronic conditions (atherosclerosis, MASH/NASH, auto-immune diseases, HIV). So--how do you price a drug that saves lives in life-threatening indications, as well as saves lives by addressing chronic conditions?
I am assuming that for acute indications you take the drug until you recover, but for chronic illnesses you would take them forever, right? (Unless of course LL cures some of these chronic conditions...) Anyway, are there any drugs out there that are priced in a two-tiered system? In other words, one price for saving a life, a lower price for managing a condition for the rest of your life?
I would think the total addressable market for LL is going to be huge. And if you have a couple hundred million patients that would benefit, why not make it affordable? You wouldn't need a high price to make a boatload of money, for us as well as Cytodyn...
* * * *
Gotta bring the NP2 connection here. Most of you know Dr. Lalezari is a founding member and Vice Chairman of the Board of the non-profit pharmaceutical corporation NP2, right? From the website, their mission is to "disrupt the current for-profit model which doesn’t work for most Americans. Incorporating as a nonprofit means that the revenues generated from our drug sales will be re-invested into furthering our mission." Now all you hardcore capitalists out there, don't get your panties/boxers in a bunch! The idea is to manufacture and distribute oncology drugs when they go generic. With no marketing expenses and minimal R&D, they think they can really lower the cost of life-saving cancer drugs, which is their initial focus.
Just connecting the dots here, and answering the pricing question I posed earlier, but when leronlimab loses patent protection, I can see NP2 contracting the rights to it, producing it and selling at an affordable price. I know its difficult to manufacture and all that, but who better to work that out than Jacob Lalezari? And with 200 to 500 million people in the world who could use it, making it affordable is actually going to be necessary... Unless you want Cytodyn to bankrupt Medicare and every other country's health insurance systems!
Lots of talk recently about extending patent protection for as long as possible... Really? I'm here to make money, but as importantly, have an up-close view of the development of a life-saving and pharma-disruptive, history-making mab! Fer Christ sakes--as my Daddy used to say--I'm sure many of us here won't even live long enough to see our mab lose patent protection! So please, take off your greedypants, count your blessings before your bank account, and think about the planet and the big picture!
(And should we live long enough to see LL go off patent, there's a decent chance it'll be because of leronlimab! That right there is all the perspective anyone needs...).
And in the meantime, as we wait on the science and the publications and the clinical trials and the partnerships with for-profit pharma, we can sleep at night in good conscience. That, my friend, is priceless!
Well, didn't start this post intending to cover all this ground, or go on this length. I'll end with a big shout out to the board. Even the greedypants! Having a place like this to learn about all things CYDY and LL--with all the distinctive personalities and unique voices--is truly priceless! (I had no clue about NP2 and the Lalezari connection until one of you posted here with the link--thanks!).
Well, check out the NP2 website at np2.org
And here's a link, if I get it to work...
[https://np2.org/what-makes-us-unique/]
(12)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼